To: Larry Liebman who wrote (4972 ) 5/26/1998 1:19:00 PM From: Rocketman Respond to of 9719
Who knows what the range of INCY royalties could be, but it wouldn't surprise me for this to be accurate. At one point long ago, after one of their first deals, the company publicized a 1% royalty rate. However, they release no financial data on deals any longer, I think partly to make it easier to negotiate more favorable deals with new partners than constantly hearing one Pharma whine about how another Pharma got a better deal. They just customize each deal instead and each Pharma has is issues resolved individually. However, at the H&Q conference in January, in answer to a question regarding royalties, CFO Denise Gilbert said something to the effect that they had not changed the structure of the royalties. However, Denise is pretty cagey, so in my mind at least, this could mean that they originally planned a 1-9% range, for example, and were within that still, or that everything was done at 1% similar to the first announced deal, or anything in between. INCY is intentionally vague in this area, but you never know what some reporter or analyst prys out of someone. It would certainly be considered more reliable info, if they name their source. I doubt that anyone has as big a force developing bioinformatics software as INCY. They really do view themselves as both a software and a biotech company. Plus, they have some pretty good partnerships in this area, and you couldn't be better located on the planet in terms of being in a hotbed area of software development. What is significant, but seems unrecognized as such by the market is the new deal with Monsanto for the GEM arrays:biz.yahoo.com <<<<<<<<< Monday May 18, 8:00 pm Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals Inc. Monsanto Initiates First Large-Scale, Genome-Wide Application of Incyte's DNA Microarrays for Functional Genomics Monsanto Will Access Up to 50,000 DNA Microarrays PALO ALTO, Calif. and ST. LOUIS, May 18 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) and Monsanto Company (NYSE: MTC - news) announced today that they have entered into an agreement whereby Incyte will provide Monsanto with broad access to Incyte's gene expression microarray technology. The three-year agreement provides Monsanto scientists with the ability to analyze up to 500 million gene expression data points using Incyte's GEM(TM) microarrays. Financial terms of the agreement were not disclosed...................... >>>>>>>>> This is their first sale of their Synteni based microarray technology. I'd love to know how this deal is structured!!! The only way we'll find out is by its impact on the Q financials or somebody like a potential customer leaking it somewhere. I would not be surprised to see them adding this product to a lot of the existing customers deals. I really like how INCY keeps introducing new product lines to expand their revenue base. I anticipate that they will continue to do this in the future in ways not yet imagined. My guess is that these microarray deals will be big revenue and profit generators and will also stimulate more demand for the database products. These can allow faster development of diagnostic tools, which have a shorter time to market than therapeutics. Looking forward to the first actual royalty generating products. However, the stock market doesn't seem to share my exuberance over this latest deal. My guess is that they just don't have a clue as to what it involves and how lucrative it could be. Rman